Bio-Techne

Bio-Techne's 15min chart triggers KDJ Golden Cross, bullish Marubozu signal.

Wells Fargo Raises Bio-Techne PT to $76 from $70, Maintains Overweight Rating

Citigroup

Citigroup raises Bio-Techne's PT to $80, maintains Buy rating.

Bio-Techne: Stifel Raises PT to $65 from $60, Maintains Hold Rating

Bio-Techne: TD Cowen maintains Buy rating, raises PT to $80 from $70.

Catalyst<ul> <li>Fund flows show positive net inflows across all order size buckets indicating accumulating institutional interest.</li></ul>Risk<ul> <li>Technical indicators show the market is in a weak state with bearish signals dominant and a risk of further decline.</li> <li>Analyst ratings show inconsistency with three Strong Buy and two Neutral ratings reflecting divided institutional sentiment.</li> <li>Fundamental factors highlight negative cash growth and declining earnings per share signaling financial performance concerns.</li></ul>

Key Factors

TECH reported Q2 FY2026 revenue of $295.9 million, flat year-over-year, and adjusted EPS of $0.46, beating the $0.43 consensus.TECH declared a quarterly dividend of $0.08 per share, payable on February 27, 2026, to shareholders of record on February 16.TECH's Q2 results were driven by margin expansion from cost discipline, with adjusted operating margin at 31.1%, up 100 basis points year-over-year.

TECH News